Avalon 2025 Lab Trend Report: Genetic Testing Soars as Routine Testing Stabilizes

Avalon 2025 Lab Trend Report: Genetic Testing Soars as Routine Testing Stabilizes

New Collaboration Initiative: Alfa Chemistry Announces Inclusion as a Listed Supplier across CHEMnetBASE Dictionaries

To make it easier for researchers to find and access the specialized chemicals they need, Alfa Chemistry has announced that it has been added as a supplier to the CHEMnetBASE dictionaries, the world’s premier collection of interactive chemistry databases from CRC Press, Taylor & Francis Group. This means that Alfa Chemistry’s vast catalog of specialized chemicals will be easily discoverable within the premier digital chemistry resource used by researchers and scientists around the world.

Vaxess Presents Data on Development of Needle-Free, Self-Applied Microarray Patch for GLP-1 Delivery

Vaxess Technologies, Inc., a biotech company developing a novel microarray patch technology to transform home delivery of therapies, is presenting new preclinical data at the 2025 American Diabetes Association (ADA) Scientific Sessions in Chicago.

Zymo Research Offers Reliable Domestic Solutions Amid Offshore Supply Chain Challenges

As supply chain instability and international backorders continue to affect the life sciences and diagnostics sectors, Zymo Research is stepping in with scalable, U.S.-based alternatives. Our latest announcement spotlights our domestic manufacturing capabilities and our role as a long-standing OEM and development partner, helping research and clinical labs maintain continuity without compromise. We believe this is especially relevant to your readers, many of whom are actively seeking reliable domestic partners. We invite you to read the full press release here: https://www.zymoresearch.com/blogs/press-releases/supply-chain-challenges

Kindeva joins forces with Rocket Science Health to pioneer new Intranasal Delivery Platform

Alithea Genomics Launches MERCURIUS™ Total DRUG-seq: A Next-Generation Full-Length Transcriptome Profiling Platform for High-Throughput Compound Screening and Target Validation

Alithea Genomics has announced the launch of MERCURIUS™ Total DRUG-seq to push the boundaries of high-throughput drug screens, toxicology screens and target validation.

Bill Kerr of Avalon Healthcare Solutions Named EY Entrepreneur Of The Year® 2025 Florida Award Winner

Bill Kerr of Avalon Healthcare Solutions Named EY Entrepreneur Of The Year® 2025 Florida Award Winner - Leader in Diagnostic Intelligence & Insights Earns Top Recognition for Transformative Work

Lindus Health Named Fierce CRO Award Winner in the Outstanding Patient Recruitment and Retention Category

Lindus Health Named a Fierce CRO Award Winner in the Outstanding Patient Recruitment and Retention Category

ZeOmega and MVP Health Care Partner to Advance Health Outcomes and Member Experience

Mursla Bio Introduces AI Precision Medicine Platform Built on Organ-Specific EV Isolation from Blood

• Platform is built on biologically labelled, organ-specific multi-omics data carried by extracellular vesicles isolated from 2ml plasma samples • Enables differentiated AI-powered biomarker discovery and IVD translation for patient stratification, therapeutic monitoring, surrogate markers and other diagnostic development programs • Publication of pre-print data, with support from Evotec International GmbH and University College London demonstrates validation of Platform’s capability for liver diseases

One2Treat, the leading company incorporating the patient voice into clinical development, launches One2Treat Voice app

One2Treat SA, a fast-growing tech company incorporating the patient voice in all strategic decisions about treatment assessments in Pharma R&D, today announced the launch of the One2Treat Voice app, a new module of their software platform.

Qureight’s synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

Qureight, a deep-learning analytics company accelerating drug development through AI-powered data curation, today announced that its digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research. The study, presented at the American Thoracic Society, demonstrates significant clinical efficacy for Avalyn’s inhaled pirfenidone (AP01), a promising treatment for idiopathic pulmonary fibrosis (IPF), a rare and high-mortality lung disease.

Thermo Fisher Scientific introduces the next generation Thermo Scientific™ Vanquish™ Charged Aerosol Detector P Series for more sensitive detection of impurities

Bio-Rad Extends Anti-Idiotypic Antibody and SpyCatcher Reagent Ranges for Bioanalysis and Antibody Drug Development

MIB Agents' Community of Families Has Awarded $2.5M in Grants to Research Pediatric Bone Cancer

MIB Agents, a leading pediatric osteosarcoma nonprofit, announced it has awarded $2.5 million in research grants through its OutSmarting Osteosarcoma program, which is powered by families honoring children affected by the disease. At its upcoming FACTOR Conference (June 26–28) in Salt Lake City, the organization will award $700,000 in grants to 10 scientists advancing less toxic, more effective treatments. The grants, which include four $100,000 Hero Grants and six $50,000 Hope Young Investigator Grants, reflect a unique collaboration between researchers and the osteosarcoma community, with families actively funding and participating in the review of scientific proposals.

Symbiosis Expands Global Reach with Key Appointment of Angelika Rublack as Senior Business Development Manager

START Launches Hope Hub to Connect Patients, Physicians, and Advocacy Groups to Community-Based Cancer Trials

The new platform is designed to break down barriers to early-phase trial access, bringing "Hope Through Access" to communities and patients who need it most.

Insilico Medicine Completes Oversubscribed Series E, Bringing Total Funding to $123 Million

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the close of its Series E financing round at a total of around $123 million, surpassing its initial target amid strong investor interest.

ClearNote Health Avantect® Pancreatic Cancer Test Enters Patient Enrollment Phase of Groundbreaking UK Study Targeting High-Risk Patients

ClearNote Health announced initiation of patient enrollment for a new study that aims to advance early detection of pancreatic cancer in individuals newly diagnosed with type 2 diabetes.

Astoriom Appoints Brittany Jackson as CFO

Key appointment to lead the company’s financial strategy and support continued global growth in sample stability and biorepository storage solutions